Drug Trial Radar · NCT06705387
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
Last checked: Nov 20, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Dec 23, 2024
Primary completion
Sep 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- University of Colorado, DenverAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- First posted
- Nov 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to \[primary purpose: e.g., learn if intervention or health behavior can treat, prevent, diagnose etc.\] in \[describe participant population/primary condition; could include any of the following: sex/gender, age groups, healthy volunteers\]. The main question\[s\] it aims to answer \[is/are\]: Does dupilumab or swallowed topical fluticasone improve the diameter of the esophagus more? Does dupilumab or swallowed topical fluticasone reduce inflammation in the esophagus more? Are comparative effective clinical trials feasible in this patient population? Researchers will compare dupilumab 300 mg weekly compared to swallowed fluticasone to see if there is a difference in treatment response. Participants will be asked to: * Be randomized to either dupilumab sq weekly or swallowed topical fluticasone twice daily. * Participate in 8 study visits over 52 weeks * Complete questionnaires * Have an endoscopy with biopsies and EndoFLIP measurements. * Swallow an Esophageal String Test
Conditions
- Eosinophilic Esophagitis
Interventions
DupilumabBiological
Subcutaneous injection of 300mg per week for 16 weeks.
FluticasoneDrug
Metered dose swallowed topical corticosteroid, given 1760mcg per day for 16 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Esophageal Lumen DistensibilityTime frame: From baseline endoscopy to the end of treatment at week 16.
- Reduction of epithelial eosinophilia to < 15 eos/hpf (binary)Time frame: This will be measured at week 16 end of treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's Hospital Colorado/University of Colorado School of Medicine
Aurora, Colorado · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.